Ober-Ramstadt, Germany

Michael Lobisch


Average Co-Inventor Count = 5.8

ph-index = 5

Forward Citations = 91(Granted Patents)


Location History:

  • Reichelsheim/Blofeld, DE (2001)
  • Ober-Ramstadt, DE (1992 - 2003)

Company Filing History:


Years Active: 1992-2003

Loading Chart...
5 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Michael Lobisch

Introduction

Michael Lobisch is a notable inventor based in Ober-Ramstadt, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative oral dosage forms. With a total of five patents to his name, Lobisch has focused on enhancing the efficacy and safety of medications.

Latest Patents

Among his latest patents, Lobisch has developed oral forms of administration containing solid flupirtine with controlled release of the active substance. This invention includes pharmaceutical dosage units that utilize a delayed-action or controlled-release component, allowing for a release rate of flupirtine between 5 and 300 mg per hour. Additionally, he has created dosage units that reduce the sedative effects of flupirtine. Another significant patent involves the treatment of migraine through the administration of α-lipoic acid or its derivatives, which can be used in both acute and chronic treatment scenarios.

Career Highlights

Throughout his career, Michael Lobisch has worked with prominent companies in the pharmaceutical industry, including Asta Medica and Viatris GmbH & Co. KG. His work has contributed to advancements in drug formulation and delivery systems, showcasing his commitment to improving patient outcomes.

Collaborations

Lobisch has collaborated with esteemed colleagues such as Bernd Nickel and Istvan Szelenyi, further enhancing the impact of his work in the pharmaceutical sector.

Conclusion

Michael Lobisch's innovative contributions to pharmaceutical science demonstrate his dedication to improving medication delivery and efficacy. His patents reflect a deep understanding of drug formulation, which continues to benefit the medical community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…